Pediatric phase i trial design using maximum target inhibition as the primary endpoint

Journal of the National Cancer Institute

Volumn 102, Issue 12, 2010, Pages 909-912

  Meany, Holly ^a,c   Balis, Frank M ^d   Aikin, Alberta ^a   Whitcomb, Patricia ^a   Murphy, Robert F ^a   Steinberg, Seth M ^b   Widemann, Brigitte C ^a   Fox, Elizabeth ^a,d  

^a Pediatric Oncology Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DIPEPTIDYL PEPTIDASE IV; TALABOSTAT; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GELATINASE; MEMBRANE PROTEIN; SEPRASE; SERINE PROTEINASE;

ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INHIBITION KINETICS; MAXIMUM TARGET INHIBITION; OPTIMAL DRUG DOSE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; EPIDEMIOLOGY; FEMALE; MALE; METHODOLOGY; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BORONIC ACIDS; CHILD; CHILD, PRESCHOOL; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GELATINASES; HUMANS; MALE; MEMBRANE PROTEINS; NEOPLASMS; RESEARCH DESIGN; SERINE ENDOPEPTIDASES;

EID: 77953699935     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq174     Document Type: Article

References (16)

1. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist. 2002;7(5):401-409.
2. Hoekstra R, Verweij J, Eskens FA. Clinical trial design for target specifc anticancer agents. Invest New Drugs. 2003;21(2): 243-250.
3. Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med. 2005;24(14):2171- 2181.
4. Morabito A, Di Maio M, De Maio E, Normanno N, Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand? Ann Oncol. 2006; 17(suppl 7):vii128-vii131.
5. Parulekar WR, Eisenhauer EA. Novel end-points and design of early clinical trials. Ann Oncol. 2002;13(suppl 4):139-143.
6. Balis FM, Fox E, Widemann BC, Adamson PC. Clinical drug development for childhood cancers. Clin Pharmacol Ther. 2009;85(2): 127-129.
7. Cunningham CC. Talabostat. Expert Opin Investig Drugs. 2007;16(9):1459-1465.
8. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004;64(15):5471-5480.
9. Cheng JD, Weiner LMTumors and their microenvironments: tilling the soil. Commentary re: A.M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fbro-blast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003
10. [comment]. Clin Cancer Res. 2003;9(5): 1590-1595.
11. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fbro-blasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87(18):7235-7239.
12. Connolly BA, Sanford DG, Chiluwal AK, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo effcacy and safety. J Med Chem. 2008;51(19):6005-6013.
13. Mentlein R. Cell-surface peptidases. Int Rev Cytol. 2004;235:165-213.
14. Sedo A, Krepela E, Kasafrek E. A kinetic fuorometric assay of dipeptidyl peptidase IV in viable human blood mononuclear cells. Biochimie. 1989;71(6):757-761.
15. Uprichard MJ, Jones BJ. Phase 1 rising multiple-dose study of talabostat (PT-100) in healthy subjects. American Society of Hematology Annual Meeting; 2004; San Diego, CA.
16. Nemunaitis J, Vukelja SJ, Richards D, et al. Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Invest. 2006;24(6):553-561.